Sigvotatug vedotin Market Summary

Key Factors Driving Sigvotatug vedotin Growth

1. Potential first-in-class IB6-targeted ADC mechanism: Sigvotatug vedotin (SV) is an investigational antibody-drug conjugate designed to target integrin beta-6 (IB6), a protein expressed at low levels in normal tissues but more highly expressed in several solid tumors, including NSCLC. The ADC delivers the cytotoxic payload monomethyl auristatin E (MMAE) directly to IB6-expressing tumor cells. This differentiated target could provide Pfizer with an opportunity to establish a new ADC class if late-stage efficacy is confirmed.

2. Encouraging early clinical activity in NSCLC: Phase I dose-expansion data published in Journal of Clinical Oncology showed an objective response rate (ORR) of 19% and median duration of response (DoR) of 11.3 months across 117 patients with advanced NSCLC. Importantly, in the clinically relevant nonsquamous, taxane-naïve population, ORR increased to 29%, with median DoR of 12.8 months, median PFS of 6.4 months, and median OS of 14.8 months. These durable responses provided the rationale for advancing SV into Phase III development.

3. First-line combination with pembrolizumab represents a major potential growth opportunity: Pfizer is evaluating SV + pembrolizumab in the Phase III SigVie-003 trial as first-line treatment for advanced/metastatic NSCLC with PD-L1 tumor proportion score ≥50%. The study plans to enroll approximately 714 patients and has dual primary endpoints of PFS and OS. Moving into first-line disease could substantially expand the eligible population and treatment duration compared with a later-line positioning. The biological rationale is also attractive because SV directly targets tumor cells while pembrolizumab activates antitumor immune responses.

4. Potential applicability across multiple solid tumors: IB6 is not restricted to NSCLC; its expression has been reported across several solid tumors. Pfizer's development strategy has therefore included investigation of SV beyond lung cancer, creating the possibility of a broader multi-tumor franchise if efficacy is demonstrated. This is particularly relevant for an ADC because successful validation of the IB6 target could allow the same drug to be developed across tumor types rather than relying on a single indication.

Sigvotatug vedotin Recent Developments

In June 2026, Pfizer announced topline results from the Phase III SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class integrin beta-6 (IB6) directed antibody-drug conjugate (ADC). The study enrolled adults with locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) who had received one or more lines of prior therapy.

• In the overall population, sigvotatug vedotin did not show a statistically significant improvement in the primary endpoint of overall survival (OS) compared to docetaxel.
• The safety profile of sigvotatug vedotin was manageable and consistent with prior studies.
• Encouragingly, in patients who received only one prior line of systemic therapy, which represents two-thirds of the study population, a stronger trend was observed for OS and progression-free survival (PFS) for sigvotatug vedotin over docetaxel.
• In the exploratory analysis, no clear IB6 expression-response relationship was observed.

“Sigvotatug vedotin Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Sigvotatug vedotin for potential indication like Non-small cell lung cancer and Solid tumours in the 7MM. A detailed picture of Sigvotatug vedotin’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Sigvotatug vedotin for potential indications. The Sigvotatug vedotin market report provides insights about Sigvotatug vedotin’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Sigvotatug vedotin performance, future market assessments inclusive of the Sigvotatug vedotin market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Sigvotatug vedotin sales forecasts, along with factors driving its market.

Sigvotatug vedotin Drug Summary

Sigvotatug vedotin (PF-08046047; formerly SGN-B6A) is an investigational antibody-drug conjugate (ADC) being developed by Pfizer that targets integrin beta-6 (αvβ6/IB6), a protein expressed at high levels in several solid tumors, including approximately 90% of non-small cell lung cancers (NSCLC). The ADC is designed to selectively bind IB6-expressing tumor cells, undergo rapid internalization, and deliver a vedotin-class auristatin payload that disrupts microtubule dynamics, leading to cancer-cell death; its ability to induce immunogenic cell death also provides a rationale for combination with immune checkpoint inhibitors. Administered by intravenous infusion, sigvotatug vedotin is being evaluated primarily in advanced/metastatic NSCLC, including previously treated disease and first-line treatment in combination with pembrolizumab. As of June 2026, the drug remained investigational; a Phase 3 study in previously treated metastatic nonsquamous NSCLC did not achieve a statistically significant overall-survival improvement versus docetaxel in the overall population, although stronger efficacy trends were observed in patients receiving it after only one prior systemic therapy. The report provides Sigvotatug vedotin’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Sigvotatug vedotin Market Report

The report provides insights into:

• A comprehensive product overview including the Sigvotatug vedotin MoA, description, dosage and administration, research and development activities in potential indication like Non-small cell lung cancer and Solid tumours.
• Elaborated details on Sigvotatug vedotin regulatory milestones and other development activities have been provided in Sigvotatug vedotin market report.
• The report also highlights Sigvotatug vedotin‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Sigvotatug vedotin market report also covers the patents information, generic entry and impact on cost cut.
• The Sigvotatug vedotin market report contains current and forecasted Sigvotatug vedotin sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Sigvotatug vedotin market report also features the SWOT analysis with analyst views for Sigvotatug vedotin in potential indications.

Methodology

The Sigvotatug vedotin market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Sigvotatug vedotin Analytical Perspective by DelveInsight

• In-depth Sigvotatug vedotin Market Assessment

This Sigvotatug vedotin sales market forecast report provides a detailed market assessment of Sigvotatug vedotin for potential indication like Non-small cell lung cancer and Solid tumours in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Sigvotatug vedotin sales data uptil 2034.

• Sigvotatug vedotin Clinical Assessment

The Sigvotatug vedotin market report provides the clinical trials information of Sigvotatug vedotin for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Sigvotatug vedotin Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Sigvotatug vedotin Market Potential & Revenue Forecast

• Projected market size for the Sigvotatug vedotin and its key indications
• Estimated Sigvotatug vedotin sales potential (Sigvotatug vedotin peak sales forecasts)
• Sigvotatug vedotin Pricing strategies and reimbursement landscape

Sigvotatug vedotin Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Sigvotatug vedotin Market positioning compared to existing treatments
• Sigvotatug vedotin Strengths & weaknesses relative to competitors

Sigvotatug vedotin Regulatory & Commercial Milestones

• Sigvotatug vedotin Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Sigvotatug vedotin Clinical Differentiation

• Sigvotatug vedotin Efficacy & safety advantages over existing drugs
• Sigvotatug vedotin Unique selling points

Sigvotatug vedotin Market Report Highlights

• In the coming years, the Sigvotatug vedotin market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Sigvotatug vedotin companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Sigvotatug vedotin’s dominance.
• Other emerging products for Non-small cell lung cancer and Solid tumours are expected to give tough market competition to Sigvotatug vedotin and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Sigvotatug vedotin in potential indications.
• Analyse Sigvotatug vedotin cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Sigvotatug vedotin sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Sigvotatug vedotin in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Sigvotatug vedotin? How strong is Sigvotatug vedotin’s clinical and commercial performance?
• What is Sigvotatug vedotin’s clinical trial status in each individual indications such as Non-small cell lung cancer and Solid tumours and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Sigvotatug vedotin Manufacturers?
• What are the key designations that have been granted to Sigvotatug vedotin for potential indications? How are they going to impact Sigvotatug vedotin’s penetration in various geographies?
• What is the current and forecasted Sigvotatug vedotin market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Sigvotatug vedotin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Sigvotatug vedotin for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Sigvotatug vedotin? What is the duration of therapy and what are the geographical variations in cost per patient?